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Figure 2. Ethidium bromide staining reveals E. 
coli starter contains recombinant plasmid.
Figure 2 displays the visualization of the agarose gel 
stained with ethidium bromide. The E. coli starter 
showed a positive band around 370-bp (ladder not 
displayed), which is the same size as the band for 
the positive control. This is also the expected size of 
the recombinant plasmid. There was no band for the 
negative control.
Legend:
Lane 1: E. coli starter Lane 3: Positive control
Lane 2: E. coli starter Lane 4: Negative control
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INTRODUCTION
Zika virus (ZIKV) is a positive-sense, single-stranded RNA arbovirus belonging to the 
genus Flavivirus in the family Flaviviridae. ZIKV transmission primarily occurs by the 
bite of an infected Aedes mosquito (Ae. aegypti and Ae. albopictus) but can also 
occur by sexual intercourse, pregnancy (mother-to-child), and blood transfusions. 
Most individuals infected with ZIKV are asymptomatic, but 20-25% of those infected 
develop a mild and self-limited illness. Symptoms include fever, arthralgia, myalgia, 
conjunctivitis, and skin rash. Severe cases of ZIKV have occurred in Micronesia, 
French Polynesia, and South America where ZIKV has been linked to Guillain-Barré 
syndrome and microcephaly. Guillain-Barré syndrome is an autoimmune disorder that 
causes muscle weakness in legs and arms, paralysis, and, in severe cases, death. 
Microcephaly is a birth defect describing a smaller-than-normal head size for infants.
ZIKV and dengue virus (DENV) have similar genomes encoding for proteins that 
make up the virus. The immune system produces antibodies against these proteins 
and can be cross-reactive between ZIKV and DENV. Protein identity for envelope (E) 
domain III is different between ZIKV and DENV by protein alignment. Antibodies 
against ZIKV E domain III are specific to ZIKV and have high neutralizing levels.
OBJECTIVE
The objective of this study was to express a recombinant ZIKV E domain III protein 
using an E. coli system. Because antibodies against ZIKV E domain III protein are 
highly specific to ZIKV, the protein may be useful for differential diagnosis between 
ZIKV and DENV and could be used for development of a rapid test kit.
MATERIALS AND METHODS
1. Creation of E. coli starter
One colony BL21 (DE3) pLysS E. coli was inoculated in LB broth with antibiotics (E. 
coli starter). The E. coli starter was incubated overnight.
2. Extraction of plasmid from E. coli starter and PCR
The recombinant plasmid was extracted from the E. coli starter. The extracted 
plasmid was amplified by PCR. After amplification, the PCR product was analyzed by 
gel electrophoresis and ethidium bromide staining. The positive band containing the 
ZIKV domain III gene was expected around 370-bp.
3. Expression of recombinant protein 
The E. coli starter with the recombinant plasmid was added to LB broth-antibiotic (E. 
coli culture). The E. coli culture was incubated until OD at 600 nm reached 0.2-0.4, 
and some E. coli culture was collected (pre-induction). The remaining E. coli culture 
was induced by IPTG and incubated for 3 hours. After incubation, some E. coli culture 
was collected (post-induction). Pre- and post-induction cultures were centrifuged to 
collect the E. coli pellet. The pellet was re-suspended with 1X PBS and sonicated on 
ice. The cell lysate was centrifuged. Four fractions were obtained: pre-induction 
supernatant, pre-induction pellet, post-induction supernatant (soluble protein), and 
post-induction pellet (insoluble protein).
4. Analysis of protein expression
The recombinant protein was separated by SDS-PAGE gel electrophoresis. After 
electrophoresis, the gel was stained with Coomassie blue to determine the presence 
of proteins in sample fractions. Another SDS-PAGE gel with the same sample 
fractions was blotted onto a nitrocellulose membrane to detect the recombinant 
protein. Anti-histidine was used to detect the six-histidine motif attached to the 
recombinant protein. The expected size of the recombinant protein is around 16kDa.
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CONCLUSIONS
The recombinant ZIKV E domain III protein was not expressed despite using E. coli
transformed with the plasmid. This may be due to multiple issues. For example, IPTG 
may not have been functioning correctly, leading to no transcription of the ZIKV E 
domain III gene. The anti-histidine system may have also malfunctioned and not 
detected the recombinant protein. Instrument error may have also occurred with the 
blotting system. Unfortunately, there was not enough time to determine why the 
recombinant protein was not expressed. 
Future directions include determining the issues with protein expression, using a 
different plasmid, or using a different gene. Based on the attempted expression of the 
recombinant ZIKV E domain III protein, developing ZIKV serodiagnostic assays can 
be challenging.
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Figure 3. Protein is present in sample 
fractions.
Figure 3 displays the Coomassie blue staining 
of the SDS-PAGE gel. All sample fractions 
have protein. 
Legend:
Lane 1: protein marker
Lane 2: pre-induction supernatant
Lane 3: pre-induction pellet
Lane 4: post-induction supernatant (soluble 
protein)
Lane 5: post-induction pellet (insoluble protein)
Figure 4. Recombinant ZIKV E 
domain III protein was not detected.
Figure 4 shows the results of the 
immunoblot. The membrane was 
reacted with anti-histidine to detect the 
six-histidine motif attached to the 
recombinant protein. The expected 
protein should be around 17-kDa. 
After reaction with anti-histidine, no 
recombinant protein was detected.
Legend: same as figure 2
Based on the 
attempted 
expression of the 
recombinant ZIKV E 
domain III protein, 
developing ZIKV 
serodiagnostic 
assays can be 
challenging
Figure 1. Infant with Microcephaly (Culjat M et al, Clin Infect 
Dis, 2016, PMID: 27193747)
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